Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||Asia Pacific Journal of Clinical Oncology, 2014; 10(3):216-227||-|
|dc.description.abstract||Major advances in the medical treatment of gastrointestinal tumors (GISTs) have improved survival for both patients with advanced disease and those diagnosed with high-risk primary tumors. The Consensus approaches to best practice management of gastrointestinal stromal tumors, published in this journal in 2008, provided guidance for the management of GIST to both clinicians and regulatory authorities. Since then, clinical trials have demonstrated the benefit of adjuvant imatinib in high-risk patients, and mature data from advanced GIST studies suggest that a small but significant proportion of patients with advanced disease can achieve long-term benefit with ongoing imatinib treatment. Other evolving management strategies include the controversial use of palliative or debulking surgery to improve outcomes in advanced GIST and the development of promising new multikinase inhibitors, such as regorafenib, which has established benefit in the third-line setting. This review provides an update of recent developments in GIST management and discusses new controversies that these advances have generated.||-|
|dc.description.statementofresponsibility||Desmond Yip, John Zalcberg, Stephen Ackland, Andrew P Barbour, Jayesh Desai, Stephen Fox, Dusan Kotasek, Grant McArthur and B Mark Smithers||-|
|dc.rights||© 2014 Wiley Publishing Asia Pty Ltd||-|
|dc.subject||adjuvant; gastrointestinal stromal tumor; molecular target therapy; imatinib; risk stratification||-|
|dc.title||Controversies in the management of gastrointestinal stromal tumors||-|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.